Walgreens Specialty Pharmacy leads RVVC care with VIVJOA exclusivity

In a move set to revolutionize treatment options for post-menopausal women and those not of reproductive potential, Walgreens specialty pharmacy patients now have exclusive access to VIVJOA, an antifungal medication manufactured by Mycovia Pharmaceuticals. VIVJOA (oteseconazole) is the first FDA-approved medication designed to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in this demographic by inhibiting fungal growth.

RVVC is a condition characterized by repeated episodes of vaginal yeast infections caused by the fungus Candida. It profoundly affects patients' comfort and quality of life, manifesting in symptoms such as itching, burning, irritation, and abnormal vaginal discharge.

Walgreens specialty pharmacy patients now have exclusive access to VIVJOA. This oral medication is formulated to block fungal CYP51, an essential enzyme for maintaining fungal cell wall integrity. This marks a significant advancement in RVVC treatment options for post-menopausal women and those not of reproductive potential.

According to Mycovia Pharmaceuticals, by undergoing a 12-week course of VIVJOA therapy, patients can significantly decrease the occurrence of RVVC for nearly a year.

"AllianceRx Walgreens Pharmacy, a subsidiary of Walgreens, announced the partnership, marking a significant advancement in specialized pharmaceutical care," said Tracey James, RPh, chief operating officer of Walgreens specialty enterprise. "This collaboration underscores our commitment to comprehensive patient care."

VIVJOA joins a lineup of exclusive limited distribution drugs available through Walgreens enterprise specialty pharmacy, reinforcing its position among the leading specialty pharmacies in the United States.

In addition to VIVJOA, patients can now access the following drugs:

• Augtyro (repotrectinib): Manufactured by Bristol Myers Squibb, Augtyro is an oral prescription medicine used to treat non-small cell lung cancer (NSCLC) in adults with specific genetic mutations.
• Eylea HD (aflibercept) injection: Developed by Regeneron, Eylea HD is approved for treating neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
• Entyvio SQ (vedolizumab): Manufactured by Takeda, Entyvio SQ is a maintenance therapy for adult patients with moderately to severely active ulcerative colitis.
• Hemady (dexamethasone): Distributed by Edenbridge Pharmaceuticals, Hemady represents a significant advancement in multiple myeloma treatment, being the first and only 20 mg tablet of dexamethasone indicated for use with other anti-myeloma products.

The introduction of VIVJOA to Walgreens' specialty pharmacy portfolio marks a significant milestone in RVVC treatment, offering hope and relief to countless individuals affected by this challenging condition.